Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
NCT06518551
Age 18 +
Sex Both
Phase Phase 1, Phase 2
Third Opinion Trial Synopsis
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. The study focuses on using a combination of therapies to improve patient outcomes. Here are some key details about the study:
- The treatment involves a unique combination of drugs that target different aspects of the disease.
- Participants will receive the treatment in a specific sequence, which is designed to maximize effectiveness.
- The study aims to evaluate how well this combination works compared to standard treatments.
- Patients will be monitored closely for side effects and overall health improvements.
- This study is notable for its focus on personalized treatment plans based on individual patient characteristics.
- Researchers are also looking at how this treatment affects patients' quality of life during and after therapy.
Third Opinion AI Generated Synopsis
Trial Summary
The aim of this research study is to evaluate the efficacy of Elotuzumab and Iberdomide therapy post-Idecabtagene Vicleucel in participants with relapsed and refractory multiple myeloma. The names of the study drugs involved in this study are: * Iberdomide (a type of cereblon E3 ligase modulator) * Elotuzumab (a type of monoclonal antibody) * Dexamethasone (a type of steroid)
The aim of this research study is to evaluate the efficacy of Elotuzumab and Iberdomide therapy post-Idecabtagene Vicleucel in participants with relapsed and refractory multiple myeloma. The names of the study drugs involved in this study are: * Iberdomide (a type of cereblon E3 ligase modulator) * Elotuzumab (a type of monoclonal antibody) * Dexamethasone (a type of steroid)
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
